Cargando…

Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor

Objectives: Farnesoid X receptor (FXR) activation is involved in ameliorating inflammatory bowel disease (IBD), such as ulcerative colitis (UC), and inflammatory regulation may be involved in its mechanism. Ginsenoside Rc (Rc) is a major component of Panax ginseng, and it plays an excellent role in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Kaijia, Kong, Danli, Peng, Yuan, Guo, Jingyi, Zhong, Yadi, Yu, Haibing, Mai, Zhenhua, Chen, Yanling, Chen, Yingjian, Cui, Tianqi, Duan, Siwei, Li, Tianyao, Liu, Naihua, Zhang, Dong, Ding, Yuanlin, Huang, Jiawen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649634/
https://www.ncbi.nlm.nih.gov/pubmed/36386150
http://dx.doi.org/10.3389/fphar.2022.1000444
_version_ 1784827839819808768
author Tang, Kaijia
Kong, Danli
Peng, Yuan
Guo, Jingyi
Zhong, Yadi
Yu, Haibing
Mai, Zhenhua
Chen, Yanling
Chen, Yingjian
Cui, Tianqi
Duan, Siwei
Li, Tianyao
Liu, Naihua
Zhang, Dong
Ding, Yuanlin
Huang, Jiawen
author_facet Tang, Kaijia
Kong, Danli
Peng, Yuan
Guo, Jingyi
Zhong, Yadi
Yu, Haibing
Mai, Zhenhua
Chen, Yanling
Chen, Yingjian
Cui, Tianqi
Duan, Siwei
Li, Tianyao
Liu, Naihua
Zhang, Dong
Ding, Yuanlin
Huang, Jiawen
author_sort Tang, Kaijia
collection PubMed
description Objectives: Farnesoid X receptor (FXR) activation is involved in ameliorating inflammatory bowel disease (IBD), such as ulcerative colitis (UC), and inflammatory regulation may be involved in its mechanism. Ginsenoside Rc (Rc) is a major component of Panax ginseng, and it plays an excellent role in the anti-inflammatory processes. Our aim is to explore the alleviative effect of Rc on dextran sulfate sodium (DSS)-induced inflammation and deficiencies in barrier function based on FXR signaling. Materials and Methods: In vitro, we treated human intestinal epithelial cell lines (LS174T) with LPS to explore the anti-inflammatory effect of Rc supplementation. In vivo, a DSS-induced IBD mice model was established, and the changes in inflammatory and barrier function in colons after Rc treatment were measured using the disease activity index (DAI), hematoxylin and eosin (H&E) staining, immunofluorescence, ELISA, and qPCR. Molecular docking analysis, luciferase reporter gene assay, and qPCR were then used to analyze the binding targets of Rc. DSS-induced FXR-knockout (FXR(−/-)) mice were used for further validation. Results: Rc significantly recovered the abnormal levels of inflammation indexes (TNF-α, IL-6, IL-1β, and NF-KB) induced by LPS in LS174T. DSS-induced C57BL/6 mice exhibited a significantly decreased body weight and elevated DAI, as well as a decrease in colon weight and length. Increased inflammatory markers (TNF-α, IL-6, IL-1β, ICAM1, NF-KB, F4/80, and CD11b displayed an increased expression) and damaged barrier function (Claudin-1, occludin, and ZO-1 displayed a decreased expression) were observed in DSS-induced C57BL/6 mice. Nevertheless, supplementation with Rc mitigated the increased inflammatory and damaged barrier function associated with DSS. Further evaluation revealed an activation of FXR signaling in Rc-treated LS174T, with FXR, BSEP, and SHP found to be upregulated. Furthermore, molecular docking indicated that there is a clear interaction between Rc and FXR, while Rc activated transcriptional expression of FXR in luciferase reporter gene assay. However, these reversal abilities of Rc were not observed in DSS-induced FXR(−/-) mice. Conclusion: Our findings suggest that Rc may ameliorate inflammation and barrier function in the intestine, which in turn leads to the attenuation of DSS-induced UC, in which Rc may potentially activate FXR signaling to protect the intestines from DSS-induced injury.
format Online
Article
Text
id pubmed-9649634
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96496342022-11-15 Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor Tang, Kaijia Kong, Danli Peng, Yuan Guo, Jingyi Zhong, Yadi Yu, Haibing Mai, Zhenhua Chen, Yanling Chen, Yingjian Cui, Tianqi Duan, Siwei Li, Tianyao Liu, Naihua Zhang, Dong Ding, Yuanlin Huang, Jiawen Front Pharmacol Pharmacology Objectives: Farnesoid X receptor (FXR) activation is involved in ameliorating inflammatory bowel disease (IBD), such as ulcerative colitis (UC), and inflammatory regulation may be involved in its mechanism. Ginsenoside Rc (Rc) is a major component of Panax ginseng, and it plays an excellent role in the anti-inflammatory processes. Our aim is to explore the alleviative effect of Rc on dextran sulfate sodium (DSS)-induced inflammation and deficiencies in barrier function based on FXR signaling. Materials and Methods: In vitro, we treated human intestinal epithelial cell lines (LS174T) with LPS to explore the anti-inflammatory effect of Rc supplementation. In vivo, a DSS-induced IBD mice model was established, and the changes in inflammatory and barrier function in colons after Rc treatment were measured using the disease activity index (DAI), hematoxylin and eosin (H&E) staining, immunofluorescence, ELISA, and qPCR. Molecular docking analysis, luciferase reporter gene assay, and qPCR were then used to analyze the binding targets of Rc. DSS-induced FXR-knockout (FXR(−/-)) mice were used for further validation. Results: Rc significantly recovered the abnormal levels of inflammation indexes (TNF-α, IL-6, IL-1β, and NF-KB) induced by LPS in LS174T. DSS-induced C57BL/6 mice exhibited a significantly decreased body weight and elevated DAI, as well as a decrease in colon weight and length. Increased inflammatory markers (TNF-α, IL-6, IL-1β, ICAM1, NF-KB, F4/80, and CD11b displayed an increased expression) and damaged barrier function (Claudin-1, occludin, and ZO-1 displayed a decreased expression) were observed in DSS-induced C57BL/6 mice. Nevertheless, supplementation with Rc mitigated the increased inflammatory and damaged barrier function associated with DSS. Further evaluation revealed an activation of FXR signaling in Rc-treated LS174T, with FXR, BSEP, and SHP found to be upregulated. Furthermore, molecular docking indicated that there is a clear interaction between Rc and FXR, while Rc activated transcriptional expression of FXR in luciferase reporter gene assay. However, these reversal abilities of Rc were not observed in DSS-induced FXR(−/-) mice. Conclusion: Our findings suggest that Rc may ameliorate inflammation and barrier function in the intestine, which in turn leads to the attenuation of DSS-induced UC, in which Rc may potentially activate FXR signaling to protect the intestines from DSS-induced injury. Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9649634/ /pubmed/36386150 http://dx.doi.org/10.3389/fphar.2022.1000444 Text en Copyright © 2022 Tang, Kong, Peng, Guo, Zhong, Yu, Mai, Chen, Chen, Cui, Duan, Li, Liu, Zhang, Ding and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Tang, Kaijia
Kong, Danli
Peng, Yuan
Guo, Jingyi
Zhong, Yadi
Yu, Haibing
Mai, Zhenhua
Chen, Yanling
Chen, Yingjian
Cui, Tianqi
Duan, Siwei
Li, Tianyao
Liu, Naihua
Zhang, Dong
Ding, Yuanlin
Huang, Jiawen
Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
title Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
title_full Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
title_fullStr Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
title_full_unstemmed Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
title_short Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
title_sort ginsenoside rc attenuates dss-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid x receptor
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649634/
https://www.ncbi.nlm.nih.gov/pubmed/36386150
http://dx.doi.org/10.3389/fphar.2022.1000444
work_keys_str_mv AT tangkaijia ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT kongdanli ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT pengyuan ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT guojingyi ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT zhongyadi ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT yuhaibing ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT maizhenhua ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT chenyanling ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT chenyingjian ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT cuitianqi ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT duansiwei ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT litianyao ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT liunaihua ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT zhangdong ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT dingyuanlin ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor
AT huangjiawen ginsenosidercattenuatesdssinducedulcerativecolitisintestinalinflammatoryandbarrierfunctionbyactivatingthefarnesoidxreceptor